Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1B Study to Determine the Safety and Tolerability and Confirm the Dose of Canakinumab and Spartalizumab in Combination With Nab-paclitaxel and Gemcitabine for Patients With Metastatic Pancreatic Cancer

Next Previous
X
Search
Trial Profile

A Phase 1B Study to Determine the Safety and Tolerability and Confirm the Dose of Canakinumab and Spartalizumab in Combination With Nab-paclitaxel and Gemcitabine for Patients With Metastatic Pancreatic Cancer

Status: Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 07 Apr 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Canakinumab (Primary) ; Gemcitabine (Primary) ; Paclitaxel (Primary) ; Spartalizumab (Primary)
  • Indications Adenosquamous carcinoma; Pancreatic cancer
  • Focus Adverse reactions
  • Acronyms PanCAN-SR1

    • Most Recent Events

    • 04 Apr 2023 Planned End Date changed from 1 Feb 2023 to 1 Aug 2023.
    • 07 Jun 2022 Initial Results (n=10)presented at the 58th Annual Meeting of the American Society of Clinical Oncology
    • 05 Apr 2022 Planned End Date changed from 1 Jun 2022 to 1 Feb 2023.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top